Bonet Jacopo, Barbieri Emiliano, Santoro Nicola, Dalla Man Chiara
Department of Information Engineering, University of Padua, Padova, Italy.
Section of Pediatrics, Department of Translational Sciences, University of Naples Federico II, Napoli, Italy.
J Diabetes Sci Technol. 2024 Jul 30:19322968241266825. doi: 10.1177/19322968241266825.
Lactate is not considered just a "waste product" of anaerobic glycolysis anymore. It has been proved to play a key role in several metabolic diseases, such as in the metabolic dysfunction-associated steatotic liver disease, obesity, and diabetes. The capability of simulating glucose-insulin-lactate interaction would be useful to design and test drugs targeting lactate metabolism in such pathological conditions. Minimal models are available, which describe and quantify glucose-lactate interaction but models to simulate postprandial glucose-insulin-C-peptide-lactate time courses are missing. The aim of this study is to fill this gap.
Starting from the Padova Type 2 Diabetes Simulator (T2DS), we first added a description of glucose-lactate kinetics and then created a population of 100 in silico subjects to match glucose-insulin-C-peptide-lactate data of 44 adolescents with/without obesity who underwent a standard oral glucose tolerance test (OGTT) of 75 g.
The developed model accurately predicts all molecules time courses, guaranteeing precise model parameter estimates (percent coefficient of variation [CV%] median [25th-75th percentile] = 19 [9-29]%). The generated in silico population shows good agreement with the clinical data in terms of area under the curve (AUC) ( = .6, .6, .9, .6 for glucose, insulin, C-peptide, and lactate, respectively) and parameter distributions ( > .1).
We have developed a simulator to describe glucose, insulin, C-peptide, and lactate kinetics during an OGTT, which captures the behavior of a real population of adolescents with/without obesity both in terms of average and intersubject variability. Such simulator can be used to investigate the pharmacodynamics of drugs targeting lactate metabolic pathway in various pathological conditions.
乳酸不再仅仅被视为无氧糖酵解的“废物”。事实证明,它在几种代谢性疾病中起着关键作用,比如在代谢功能障碍相关的脂肪性肝病、肥胖症和糖尿病中。模拟葡萄糖 - 胰岛素 - 乳酸相互作用的能力,对于设计和测试针对此类病理状况下乳酸代谢的药物将是有用的。现有的最小模型可描述和量化葡萄糖 - 乳酸相互作用,但缺少模拟餐后葡萄糖 - 胰岛素 - C肽 - 乳酸时间进程的模型。本研究的目的就是填补这一空白。
从帕多瓦2型糖尿病模拟器(T2DS)出发,我们首先添加了葡萄糖 - 乳酸动力学的描述,然后创建了100个虚拟受试者群体,以匹配44名有/无肥胖症的青少年在接受75克标准口服葡萄糖耐量试验(OGTT)时的葡萄糖 - 胰岛素 - C肽 - 乳酸数据。
所开发的模型能够准确预测所有分子的时间进程,确保精确的模型参数估计(变异系数百分比[CV%]中位数[第25 - 75百分位数] = 19 [9 - 29]%)。生成的虚拟群体在曲线下面积(AUC)方面(葡萄糖、胰岛素、C肽和乳酸的AUC分别为0.6、0.6、0.9、0.6)和参数分布方面(> 0.1)与临床数据显示出良好的一致性。
我们开发了一种模拟器来描述OGTT期间葡萄糖、胰岛素、C肽和乳酸的动力学,该模拟器在平均水平和个体间变异性方面都捕捉到了有/无肥胖症的真实青少年群体的行为。这种模拟器可用于研究针对各种病理状况下乳酸代谢途径的药物的药效学。